Mavacamten Targets Adolescent H. C. M. 03/31/26
Welcome to Cardiology Today â Recorded March 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and intermediate coronary lesions. Key takeaway: Mavacamten Targets Adolescent H. C. M..
Article Links:
Article 1: IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. (The New England journal of medicine)
Article 2: Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI. (The New England journal of medicine)
Article 3: Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. (The New England journal of medicine)
Article 4: Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine)
Article 5: Angiography-Derived Fractional Flow Reserve to Guide PCI. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/
đ Featured Articles
Article 1: IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41911017
Summary: Percutaneous coronary intervention for unprotected left main coronary artery disease is a critical revascularization strategy in cardiology. The comparative effectiveness of intravascular ultrasonographic guidance versus conventional angiographic guidance in improving clinical outcomes for P. C. I. remains an area of active investigation. Clarifying the optimal guidance method holds significant implications for patient prognosis in this high-risk population.
Article 2: Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41911016
Summary: Intravascular ultrasonography guidance during percutaneous coronary intervention has been associated with increased stent optimization and reduced adverse events in patients with complex coronary artery lesions. Despite these recognized benefits and practice guideline recommendations for intracoronary imaging in anatomically complex lesions, adoption of this strategy in Western countries remains low. This highlights an ongoing need for robust evidence supporting its broader clinical integration in high-risk P. C. I. procedures.
Article 3: Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910427
Summary: The long-term role of beta-blocker therapy after a myocardial infarction is currently undefined for patients with preserved left ventricular systolic function and without heart failure, particularly in the era of modern reperfusion and secondary prevention. This clinical uncertainty impacts decisions regarding medication continuation for stable post-myocardial infarction patients. Resolving this question has substantial implications for reducing polypharmacy and tailoring post-event care.
Article 4: Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910394
Summary: Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are currently lacking, often leading to surgical intervention for left ventricular outflow tract obstruction. Mavacamten, a cardiac myosin inhibitor, is an established treatment for adults with obstructive hypertrophic cardiomyopathy. Evaluating the efficacy and safety of mavacamten in symptomatic adolescents with this condition addresses a critical unmet therapeutic need for younger patients.
Article 5: Angiography-Derived Fractional Flow Reserve to Guide PCI.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910384
Summary: Physiological assessment of intermediate coronary lesions using an intracoronary pressure wire demonstrably improves clinical outcomes for patients undergoing cardiac catheterization and percutaneous coronary intervention. However, the widespread clinical adoption of pressure-wire-based physiological assessment remains limited. Angiography-derived fractional flow reserve shows good correlation with pressure-wire-based measurements and can simplify procedures, but its definitive impact on patient clinical outcomes remains unestablished.
đ Transcript
Today’s date is March 31, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. Percutaneous coronary intervention for unprotected left main coronary artery disease is a critical revascularization strategy in cardiology. The comparative effectiveness of intravascular ultrasonographic guidance versus conventional angiographic guidance in improving clinical outcomes for P. C. I. remains an area of active investigation. Clarifying the optimal guidance method holds significant implications for patient prognosis in this high-risk population.
Article number two. Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI. Intravascular ultrasonography guidance during percutaneous coronary intervention has been associated with increased stent optimization and reduced adverse events in patients with complex coronary artery lesions. Despite these recognized benefits and practice guideline recommendations for intracoronary imaging in anatomically complex lesions, adoption of this strategy in Western countries remains low. This highlights an ongoing need for robust evidence supporting its broader clinical integration in high-risk P. C. I. procedures.
Article number three. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. The long-term role of beta-blocker therapy after a myocardial infarction is currently undefined for patients with preserved left ventricular systolic function and without heart failure, particularly in the era of modern reperfusion and secondary prevention. This clinical uncertainty impacts decisions regarding medication continuation for stable post-myocardial infarction patients. Resolving this question has substantial implications for reducing polypharmacy and tailoring post-event care.
Article number four. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are currently lacking, often leading to surgical intervention for left ventricular outflow tract obstruction. Mavacamten, a cardiac myosin inhibitor, is an established treatment for adults with obstructive hypertrophic cardiomyopathy. Evaluating the efficacy and safety of mavacamten in symptomatic adolescents with this condition addresses a critical unmet therapeutic need for younger patients.
Article number five. Angiography-Derived Fractional Flow Reserve to Guide PCI. Physiological assessment of intermediate coronary lesions using an intracoronary pressure wire demonstrably improves clinical outcomes for patients undergoing cardiac catheterization and percutaneous coronary intervention. However, the widespread clinical adoption of pressure-wire-based physiological assessment remains limited. Angiography-derived fractional flow reserve shows good correlation with pressure-wire-based measurements and can simplify procedures, but its definitive impact on patient clinical outcomes remains unestablished.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
heart failure, intermediate coronary lesions, beta-blocker therapy, stent optimization, cardiac myosin inhibitor, angiography, percutaneous coronary intervention, adolescents, pressure-wire assessment, complex coronary artery lesions, unprotected left main coronary artery disease, adverse events, angiography-derived F. F. R., left ventricular systolic function, mavacamten, intravascular ultrasonography, hypertrophic cardiomyopathy, fractional flow reserve, left ventricular outflow tract obstruction, myocardial infarction, secondary prevention, clinical outcomes.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow